The role of partnership in the pharmaceutical industry is ever increasing in realising the business goals. Our presentation provides a partnering scorecard for the year 2018. It also provides a pipeline gap analysis which is one of the key drivers for partnerships in pharmaceutical industry. The presentation also benchmarks the […]
Rare Disease Situation Analysis is aimed at providing a high level glimpse into the rare disease drug development and commercialization. Rare disease drug development has been an increasingly attractive proposition for biopharmaceutical companies.
This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
The presentation gives some key insights on the emerging biosimilars developer landscape with focus on US, EU, China, Japan, South Korea, MENA and Indian markets. Furthermore, it provides a detailed analysis on Clinical differentiation of players for major products (Bevacizumab, Trastuzumab, Adalimumab, Rituximab, Infliximab and etanercept).
The currently approved direct oral anti-coagulants have proven to be safe and efficacious in prevention of stroke in patients with AF. However, the choice of DOAC is influenced by several factors including specific patient characteristics (renal function etc.), preference of OD versus BID, physicians comfort with the drug and the cost of drug to the patient.
Indian start-up ecosystem has been steadily growing with over 5200 start-ups in the country today. India has become the world’s third-largest start-up ecosystem, and is projected to cross 10,000 by 2020! This presentation throws light on the healthcare (health-tech) start-up landscape of the country and provides an overview of the funding […]